XML 47 R22.htm IDEA: XBRL DOCUMENT
v3.25.3

Net Loss Per Share | 12 Months Ended
--- | ---
Sep. 30, 2025
Earnings Per Share [Abstract] |
Net Loss Per Share | NET LOSS PER SHARE The following table presents the computation of basic and diluted net loss per share for the years ended September 30, 2025, 2024 and 2023.
|  | Year Ended September 30,
|  | 2025 |  | 2024 |  | 2023
|  | (in thousands, except per share amounts)
Numerator: |  |  |  |  |  |
Net loss attributable to Arrowhead Pharmaceuticals, Inc. |  | $ | (1,631) |  |  | $ | (599,493) |  |  | $ | (205,275) |
Denominator: |  |  |  |  |  |
Weighted-average basic shares outstanding (1) |  | 133,758 |  |  | 119,784 |  |  | 106,750 |
Effect of dilutive securities |  | — |  |  | — |  |  | — |
Weighted-average diluted shares outstanding (1) |  | 133,758 |  |  | 119,784 |  |  | 106,750 |
Basic net loss per share |  | $ | (0.01) |  |  | $ | (5.00) |  |  | $ | (1.92) |
Diluted net loss per share |  | $ | (0.01) |  |  | $ | (5.00) |  |  | $ | (1.92) |
(1) Includes shares of common stock into which the Avoro Pre-Funded Warrants may be exercised. See Note 6. The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive.
|  | Year Ended September 30,
|  | 2025 |  | 2024 |  | 2023
|  | (in thousands)
Options |  | 744 |  |  | 707 |  |  | 633 |
Restricted stock units |  | 4,276 |  |  | 4,030 |  |  | 3,420 |
Total |  | 5,020 |  |  | 4,737 |  |  | 4,053 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration